United Therapeutics Corporation - Common Stock (UTHR)
418.25
+8.38 (2.04%)
NASDAQ · Last Trade: Sep 19th, 12:17 PM EDT
Detailed Quote
Previous Close
409.87
Open
408.75
Bid
416.37
Ask
418.23
Day's Range
408.75 - 419.26
52 Week Range
266.98 - 436.95
Volume
266,564
Market Cap
18.78B
PE Ratio (TTM)
16.31
EPS (TTM)
25.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
880,066
Chart
About United Therapeutics Corporation - Common Stock (UTHR)
United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapies to treat chronic and life-threatening conditions, primarily in the fields of pulmonary hypertension and organ transplantation. Through its research efforts, the company aims to create and provide advanced medications that improve the quality of life for patients with severe health challenges. United Therapeutics is also engaged in initiatives to promote organ donation and transplantation, working towards enhancing the availability of organs for patients in need. Read More
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
United Therapeutics currently trades at $412.41 and has been a dream stock for shareholders. It’s returned 308% since September 2020, tripling the S&P 500’s 103% gain. The company has also beaten the index over the past six months as its stock price is up 29.3%.
United Therapeutics (UTHR) aligns with Peter Lynch's GARP strategy, featuring strong EPS growth, a PEG below 1, zero debt, and robust financial health.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, will provide an overview and update on the company during a fireside chat session at the Bernstein 2nd Annual Healthcare Forum in New York.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands on September 27 - October 1, 2025.
United Therapeutics (UTHR) is a strong value investing candidate with low P/E, zero debt, high profitability, and excellent financial health, offering a solid margin of safety.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity (FVC) relative to placebo.
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s operations during a fireside chat session at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.
United Therapeutics (UTHR) exemplifies Peter Lynch's GARP strategy with strong EPS growth, zero debt, and an undervalued PEG ratio. A model for long-term investors.
